# Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

> **NCT04370093** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Nephrolithiasis, Uric Acid

## Interventions

- **DRUG:** Pioglitazone 45 mg
- **BEHAVIORAL:** Weight Loss
- **OTHER:** Pioglitazone + Weight Loss

## Key facts

- **NCT ID:** NCT04370093
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04370093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04370093, "Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04370093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*